← Therapy pipeline
Investigational · Obesity development

EloraTZP

eloralintide + tirzepatide · Eli Lilly

Eloralintide is added to tirzepatide as a distinct obesity strategy.

amylinGLP-1GIP
Other study areas
Type 2 diabetes
Selected program areas, not approvals. See the full profile for individual trials.
Obesity stagePhase 3Updated as of November 2026
SponsorEli Lilly
Targetsamylin + GLP-1 + GIP
RouteInjection
DevelopmentObesity-specific
01 / Evidence

Selected study results

EloraTZP Phase 2bMean body-weight change · primary endpointBody weight decreased 23.3% · 48 weeks · Phase 2b
Phase 2b · Injection · Sponsor-reported Phase 2b results

Mean body-weight change · primary endpoint · 48 weeks

Study focus: Weight management with type 2 diabetes

Eloralintide 9 mg + tirzepatide 15 mg
23.3%
Placebo
3%

Adults with obesity or overweight and type 2 diabetes · Once weekly, as separate injections · Trial N=367 · Efficacy estimand; sponsor-reported EASD results. Results & methods ↗

Same study · efficacy estimand at week 48
Weekly regimenWeight changeHbA1c change (pp)
Eloralintide 3 mg + tirzepatide 5 mg−13.2%−2.2
Eloralintide 6 mg + tirzepatide 5 mg−19.4%−2.7
Eloralintide 6 mg + tirzepatide 10 mg−19.9%−2.6
Eloralintide 9 mg + tirzepatide 15 mg−23.3%−2.9
Tirzepatide 15 mg−14.8%−2.4
Eloralintide 3 mg−8.2%−1.1
Eloralintide 6 mg−12.3%−1.4
Eloralintide 9 mg−11.1%−1.3
Placebo−3.0%−0.3

Primary comparison: combination versus placebo; comparisons with tirzepatide were secondary. Baseline mean weight 105.4 kg and HbA1c 8.1%. These results have not been verified against a journal publication.

Each graphic shows results within one study. Alternate analyses and follow-up from that study are labeled together. Study averages are not individual predictions or cross-trial comparisons.

Tolerability

Safety context

Adverse-event discontinuation: 10.8–27.0% across combination arms, 0–10.8% with eloralintide, 2.9% with tirzepatide and 16.7% with placebo. The combination range is not assigned to individual doses.

02 / How it works

Mechanism at a glance

GLP-1GLP-1Targeted
GIPGIPTargeted
GCGglucagon—
AMYamylinTargeted
OTHOther targets—
Explore the hormone anatomy ↗
03 / Development

Obesity stage by formulation

Eloralintide + tirzepatideInjection · Once weekly
Phase 3AMPLIFY-2 recruiting; AMPLIFY-1 registered, not yet recruiting
Milestone → next

Latest: AMPLIFY-2 Phase 3 began October 16, 2026, and is recruiting per the November 4 registry update. The separate AMPLIFY-1 Phase 3 study is registered, not yet recruiting.

Next: Phase 3 AMPLIFY recruitment and outcomes; the reported Phase 2b study used separate injections.

04 / Study records

Clinical study records

Obesity and weight-management studies appear first. Related-condition trials follow by phase, with focus labels to show what each study evaluates. Study stage and results reporting are listed separately. Results summarized above are identified as peer-reviewed or sponsor reported. Otherwise, the label states whether results were posted to a registry or reported in the linked source.

Obesity and weight-management studies

Phase 3 studies2 records

Phase 3

AMPLIFY-1

Weight management without type 2 diabetes
Study: Planned / not yet recruitingResults: No registry results posted yetStatus reviewed November 2026

Registered Phase 3 in an estimated 2,115 adults with obesity without type 2 diabetes; week-100 weight endpoint, not yet recruiting, with an estimated December 2026 start.

Phase 3

AMPLIFY-2

Combination weight management with type 2 diabetes
Study: OngoingResults: No registry results posted yetStatus reviewed November 2026

Phase 3 in an estimated 1,000 adults with overweight or obesity and type 2 diabetes; EloraTZP versus tirzepatide, with a week-100 weight endpoint. Actual start October 16, 2026.

Phase 2 studies1 record

Phase 2

EloraTZP type 2 diabetes study

Combination weight management with type 2 diabetes
Study: CompletedResults: Sponsor-reported Phase 2b results shown aboveStatus reviewed November 2026

48-week randomized, double-blind Phase 2b study in 367 adults with overweight or obesity and type 2 diabetes; separate injections. Primary weight comparison with placebo; other comparisons secondary.

Related conditions and outcomes

Phase 2 studies1 record

Phase 2

Eloralintide + tirzepatide study

Combination development
Study: CompletedResults: No registry results posted yetStatus reviewed November 2026

Registered study of eloralintide and eloralintide plus tirzepatide in adults with overweight or obesity; see registry for design details.